Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines.
Dermatol Surg
; 46(5): 653-661, 2020 05.
Article
em En
| MEDLINE
| ID: mdl-31625954
ABSTRACT
BACKGROUND:
Millennials (aged 18-34 years) represent a growing segment of the facial aesthetic market.OBJECTIVE:
To evaluate investigator-assessed efficacy, patient-reported outcomes (PROs), and safety for millennials versus subjects aged at least 35 years after onabotulinumtoxinA treatment of forehead lines (FHL) across 2 phase 3 studies.METHODS:
Eligible subjects with moderate to severe FHL received onabotulinumtoxinA (FHL 20 U; glabellar lines 20 U, with/without 24 U in crow's feet line regions) or placebo. All findings were pooled by the age group.RESULTS:
Millennials composed 15% of subjects (176/1,178). Day 30 responder rates of at least 1-grade Facial Wrinkle Scale improvement in FHL severity for millennials versus subjects aged 35 years and older were 100% versus 97.8% at maximum eyebrow elevation and 78.4% versus 83.5% at rest, respectively. Responder rates were significantly greater with onabotulinumtoxinA than placebo (p ≤ .015) for both groups through Day 180. Similar trends were observed for achieving none/mild severity. Both age groups reported high satisfaction rates and improved psychological impacts with onabotulinumtoxinA treatment. No new safety signals were detected.CONCLUSION:
OnabotulinumtoxinA treatment was well tolerated, and both age groups experienced significant improvements in FHL severity, high satisfaction, and improved psychological impacts after treatment. Millennials reported numerically greater improvements.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Envelhecimento da Pele
/
Técnicas Cosméticas
/
Toxinas Botulínicas Tipo A
/
Testa
/
Fármacos Neuromusculares
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article